Demography, patient characteristics, and results summary
| Perindopril (n=31) | Placebo (n=35) | |
|---|---|---|
| Data are numbers unless otherwise stated. | ||
| *Based on patients' history and information from case notes. | ||
| IHD, ischaemic heart disease. | ||
| Age ( years) (mean (SD)) | 81.3 (6.2) | 80.7 (5.2) |
| Male:female | 18:13 | 15:20 |
| New York Heart Association functional class | ||
| I/II | 1/15 | 1/12 |
| III/IV | 14/1 | 21/1 |
| Smoking status | ||
| Never | 13 | 18 |
| Former/current | 16/2 | 15/2 |
| Medical history* | ||
| Atrial fibrillation | 12 | 9 |
| IHD | 15 | 21 |
| Hypertension | 8 | 17 |
| Diabetes | 2 | 7 |
| Peripheral vascular disease | 4 | 4 |
| Cerebrovascular accident | 5 | 8 |
| Obstructive airways disease | 8 | 10 |
| Medication | ||
| Prescribed diuretic | 26 | 31 |
| Mean dose furosemide (mg) | 54 | 50 |
| Spironolactone | 2 | 4 |
| Non-steroidal | 1 | 1 |
| Aspirin | 12 | 15 |
| Warfarin | 9 | 6 |
| Use of inhalers | 6 | 11 |
| Digoxin | 13 | 9 |
| β Blocker | 2 | 4 |
| Calcium antagonist | 6 | 9 |
| Nitrate | 1 | 7 |
| Mental score questionnaire (median) | 10 | 9 |
| Left ventricular systolic dysfunction aetiology* | ||
| IHD | 9 | 13 |
| Hypertension | 2 | 5 |
| IHD and hypertension | 6 | 11 |
| Unknown | 14 | 6 |
| Significant valve disease | ||
| Mitral regurgitation | 12 | 15 |
| Tricuspid regurgitation | 6 | 7 |
| Aortic regurgitation | 6 | 9 |